Clinical Trials Sponsored by Japan Breast Cancer Research Group

Total 1066 results

Japan Breast Cancer Research Group
Chugai Pharmaceutical

Completed

Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer (BOOSTER)

Metastatic Breast Cancer

Japan
Pfizer
Japan Breast Cancer Research Group (JBCRG)

Completed

Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy (JBCRG-26)

Breast Cancer

Japan
Japan Breast Cancer Research Group
Chugai Pharmaceutical

Unknown

A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer (PRECIOUS)

HER2-positive Locally Advanced or Metastatic Breast Cancer

Japan
Japan Breast Cancer Research Group
Eisai Co., Ltd.

Recruiting

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

Breast Cancer

Japan
Japan Breast Cancer Research Network

Completed

Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer

Breast Neoplasms

Japan
Japan Breast Cancer Research Network

Terminated

Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer

Breast Neoplasms

Japan
SOLTI Breast Cancer Research Group

Recruiting

Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (RADIOLA)

Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-negative Breast Cancer

Spain
SOLTI Breast Cancer Research Group

Terminated

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer (NEREA)

Breast Cancer

Spain, Portugal
Spanish Breast Cancer Research Group

Active, not recruiting

Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer (NIKOLE)

Metastatic Breast Cancer

Spain
Spanish Breast Cancer Research Group

Completed

Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer (ChangHER-SC)

Breast Cancer

Spain
SOLTI Breast Cancer Research Group

Completed

SOLTI Breast Cancer Molecular Screening Program (AGATA) (AGATA)

Metastatic Breast Cancer

Spain
SOLTI Breast Cancer Research Group

Not yet recruiting

HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan (ACROSS-TROP2)

Breast Cancer Stage IV

Spain
SOLTI Breast Cancer Research Group

Recruiting

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer (SOLTI-2104)

Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Premenopausal Breast Cancer

Spain
Spanish Breast Cancer Research Group

Recruiting

Registry Study of Pregnancy and Breast Cancer (EMBARCAM)

Breast Cancer and Pregnancy

Spain
SOLTI Breast Cancer Research Group

Completed

Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer (PATRICIA II)

Metastatic Breast Cancer

Spain
SOLTI Breast Cancer Research Group

Terminated

Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC (ARIANNA)

Breast Cancer

Spain
SOLTI Breast Cancer Research Group

Completed

Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer (ONAWA)

Breast Cancer

Spain
SOLTI Breast Cancer Research Group

Completed

Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer (Opti-HER)

Breast Cancer

Spain
Novartis Pharmaceuticals
Breast International Group; German Breast Group; SOLTI Breast Cancer Research...

Completed

NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer (NeoPHOEBE)

HER2-positive Newly Diagnosed, Primary Breast Cancer

Austria, Spain, Australia, Germany
Genentech, Inc.
Breast International Group; SOLTI Breast Cancer Research Group; Austrian Breast...

Completed

A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)

Breast Cancer

United States, United Kingdom, Germany, Australia, Austria, Belgium, Brazil, France, Guatemala, Italy, Korea, Republic of, Panama, Poland, Portugal, Spain, Czechia, Hungary, Mexico, Peru, Switzerland, El Salvador, Chile
Spanish Breast Cancer Research Group
Hoffmann-La Roche; German Breast Group

Completed

Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women

Breast Cancer

Spain, Germany
Novartis Pharmaceuticals
Breast International Group; SOLTI Breast Cancer Research Group

Completed

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study (Neo ALTTO)

Neoplasms, Breast

France, Spain, United Kingdom, Belgium, Argentina, Czechia, Germany, Italy, Norway, Russian Federation, Sweden, Taiwan, Hong Kong, Brazil, Hungary, India, Korea, Republic of, Pakistan, Peru, Romania, South Africa, Ukraine, Canada, Lit...
Lund University Hospital
Danish Breast Cancer Cooperative Group; Swedish Breast Cancer Group; Finnish... and other collaborators

Recruiting

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Breast Cancer | Triple Negative Breast Neoplasms

Denmark, Sweden
Spanish Breast Cancer Research Group
Sanofi

Completed

Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment

Breast Neoplasms

Spain
Spanish Breast Cancer Research Group
Novartis

Completed

Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients (EDALINE)

Advanced Breast Cancer

Spain
Spanish Breast Cancer Research Group
Novartis

Completed

Pamidronate Administration in Breast Cancer Patients With Bone Metastases

Breast Cancer | Neoplasm Metastasis

Spain
Spanish Breast Cancer Research Group
AstraZeneca

Completed

Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (COMETABreast)

Advanced Breast Cancer

Spain
Spanish Breast Cancer Research Group
AstraZeneca

Active, not recruiting

Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer (FLIPPER)

Breast Neoplasms

Spain, Ireland
Spanish Breast Cancer Research Group
Sanofi

Completed

Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients

Breast Cancer

Spain
German Breast Group
German Adjuvant Breast Cancer Group

Completed

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer

Primary Breast Cancer

Germany
Spanish Breast Cancer Research Group
AstraZeneca

Recruiting

Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab (TRANSCENDER)

Metastatic Breast Cancer | Locally Advanced Breast Cancer

Spain
SOLTI Breast Cancer Research Group
Novartis

Recruiting

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors (ACROPOLI)

Melanoma | Sarcoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Uterine Carcinosarcoma | Mesothelioma | Cholangiocarcinoma | Lung Adenocarcinoma | Triple Negative Breast Cancer | Epithelial Ovarian Cancer | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal... and other conditions

Spain
Spanish Breast Cancer Research Group
Pfizer

Completed

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

Breast Cancer

Spain
Spanish Breast Cancer Research Group
GlaxoSmithKline

Completed

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

Breast Cancer

Spain
Spanish Breast Cancer Research Group
Celgene

Completed

Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer

Breast Cancer

Spain
Spanish Breast Cancer Research Group
Pfizer

Completed

Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients

Breast Cancer

Spain
SOLTI Breast Cancer Research Group
Novartis

Completed

PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer (PAMELA)

Breast Cancer

Spain
Spanish Breast Cancer Research Group
AstraZeneca

Terminated

Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole

Breast Cancer

Spain
SOLTI Breast Cancer Research Group
Pfizer

Completed

Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy (PROMETEO II)

Breast Cancer

Spain
SOLTI Breast Cancer Research Group
Novartis

Completed

Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer. (CORALLEEN)

Breast Cancer

Spain
Spanish Breast Cancer Research Group
Novartis

Terminated

Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions

Breast Cancer | Neoplasm Metastasis

Spain
Sanofi
SOLTI Breast Cancer Research Group

Completed

Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients (SOLTI NEOPARP)

Breast Cancer Female

Spain, France, Germany
Norwegian Breast Cancer Group

Completed

Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC

Breast Neoplasm

Norway
Finnish Breast Cancer Group

Completed

BREAST CANCER AND EXERCISE (BREX)

Improve Quality of Life | Prevent Osteoporosis and Osteoporotic Fractures | Improve Weight Control, and Muscular and Cardiovascular Fitness | Help the Patients to Return to Working Life | Reduce the Risk of Breast Cancer Recurrence | Reduce All-cause Mortality in Patients With Primary Breast...

Finland
Finnish Breast Cancer Group

Completed

The Synergism Or Long Duration (SOLD) Study (SOLD)

Breast Neoplasms

Finland
SOLTI Breast Cancer Research Group
Novartis; UNICANCER

Recruiting

Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer (RIBOLARIS)

Breast Cancer Stage II

Spain, France, Portugal
SOLTI Breast Cancer Research Group
Eisai Inc.

Completed

Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer (NeoEribulin)

Breast Cancer

Spain, France, Portugal, Germany
SOLTI Breast Cancer Research Group
Schering-Plough

Completed

Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years (CAPRICE)

Breast Cancer

Spain
Cantargia AB
Spanish Breast Cancer Research Group

Recruiting

Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. (TRIFOUR)

Triple Negative Breast Cancer

Spain
Spanish Breast Cancer Research Group
Schering-Plough

Completed

Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer

Breast Cancer

Spain

Clinical Trials Sponsored by Japan Breast Cancer Research Group

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations